Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens

Todd D. Prickett1, Jessica S. Crystal1, Cyrille J. Cohen2, Anna Pasetto1, Maria R. Parkhurst1, Jared J. Gartner1, Xin Yao1, Rong Wang3, Alena Gros1, Yong F. Li1, Mona El-Gamil1, Kasia Trebska-McGowan1, Steven A. Rosenberg1, and Paul F. Robbins1

Abstract

Immunotherapy treatment of patients with metastatic cancer has assumed a prominent role in the clinic. Durable complete response rates of 20% to 25% are achieved in patients with metastatic melanoma following adoptive cell transfer of T cells derived from metastatic lesions, responses that appear in some patients to be mediated by T cells that predominantly recognize mutated antigens. Here, we provide a detailed analysis of the reactivity of T cells administered to a patient with metastatic melanoma who exhibited a complete response for over 3 years after treatment. Over 4,000 nonsynonymous somatic mutations were identified by whole-exome sequence analysis of the patient’s autologous normal and tumor cell DNA. Autologous B cells transfected with 720 mutated minigenes corresponding to the most highly expressed tumor cell transcripts were then analyzed for their ability to stimulate the administered T cells. Autologous tumor-infiltrating lymphocytes recognized 10 distinct mutated gene products, but not the corresponding wild-type products, each of which was recognized in the context of one of three different MHC class I restriction elements expressed by the patient. Detailed clonal analysis revealed that 9 of the top 20 most prevalent clones present in the infused T cells, comprising approximately 24% of the total cells, recognized mutated antigens. Thus, we have identified and enriched mutation-reactive T cells and suggest that such analyses may lead to the development of more effective therapies for the treatment of patients with metastatic cancer. Cancer Immunol Res; 4(8); 669–78. ©2016 AACR.

Introduction

Immunotherapy has assumed a prominent role in the treatment of patients with metastatic cancer (1, 2). Complete durable tumor regressions have also been observed in 20% of melanoma patients receiving adoptive transfer of autologous tumor-infiltrating lymphocytes (TIL) that were expanded in vitro to cell numbers as high as $2 \times 10^{11}$ T cells (3). Recent clinical trials that block interactions of inhibitory receptors such as CTLA-4 and PD-1 that are expressed on activated T cells have resulted in objective clinical responses in 30% to 40% of patients with melanoma (4), as well as 15% of patients with advanced squamous non–small cell lung cancer (5), and 43% of selected patients with metastatic urothelial bladder cancer (6). These observations indicate that T cells recognize antigens expressed by patients’ tumors. Clinical responses to adoptive immunotherapy have been associated with the transfer of TILs that predominantly or exclusively recognize mutated T-cell epitopes expressed by patient tumors (7–9). Direct evidence that T cells recognizing neoantigens may be important in tumor regression mediated by TILs is shown by the partial regression of a metastatic cholangiocarcinoma, still ongoing 20 months after transfer of a patient’s autologous T cells that recognized a mutated class II–restricted ERBB2IP gene product (10). Observations made in patients receiving antibodies blocking the inhibitory molecules CTLA-4 (11) and PD-1 (12), as well as in mouse tumor models (13), suggest that checkpoint blockade responses may be associated with T-cell responses to mutated tumor antigens.

Extensive studies have focused on the identification of potential tumor rejection antigens in an attempt to derive principles that can guide future cancer immunotherapies. Toward this end, we evaluated the reactivity of T cells administered to a 54-year-old man with metastatic melanoma who exhibited a complete and durable regression of metastatic disease that is ongoing over 3 years after treatment. The approach used in these studies was based upon methods described in two recent studies from our laboratory indicating that mutated antigens recognized by patient TILs could be readily identified by whole-exome sequencing of autologous tumor samples (7, 9). We identified dominant antigens recognized by a polyclonal population of in vitro expanded TILs. Whole-exome sequencing of the patient’s tumor and normal cells was initially carried out to identify nonsynonymous somatic variants present in the patient’s cancer. These variants were then aligned with those identified using RNA-Seq analysis of the same sample to generate a panel of candidate neoepitopes. Large-scale screening carried out with autologous B cells transfected with tandem minigene (TMG) constructs encoding candidate epitopes demonstrated that the
bulk population of T cells used for patient treatment recognized 10 MHC class I–restricted neoepitopes, but exhibited little or no recognition of the corresponding wild-type epitopes. The predominance of T cells that recognize the mutated epitopes in the population of administered T cells suggests that they may have played a significant role in mediating the long-term durable tumor regression seen in this patient, and provide support for continuing studies to identify and isolate T cells reactive with mutated epitopes for patient treatments.

**Materials and Methods**

**Patient tissues and cell lines**

Patient 3713 was a 54-year-old man with stage IV melanoma with multiple metastases to the lungs and lymph nodes (Fig. 1A and B). This patient underwent surgical resection of a metastatic lung lesion. TILs were grown from multiple tumor fragments, and Epstein-Barr virus (EBV)–transformed B cells were generated as described (14). In addition, a cell line was generated by culturing a fragment of the same metastatic lesion in 10% FBS and RPMI media. Selected TIL fragments were expanded in vitro, combined, and infused into the patient following a lymphodepleting regimen of nonmyeloablative chemotherapy plus 1,200 cGy of total body irradiation as described (NCI clinical trial NCT01319565). After receiving $6 \times 10^{11}$ TILs and 4 doses of high-dose IL2, the patient experienced a complete durable tumor regression that is ongoing more than 3 years after treatment (Fig. 1C and D).

The autologous tumor cell line 3713 TC and 3713 EBV-transformed B cells were generated in house shortly after tumor resection (2013). HEK-293T and COS-7 cells were purchased from the American Type Culture Collection in 2008 and cultured in RPMI-1640 (Life Technologies) media supplemented with 5% FBS, neither cell line has been authenticated recently. Patient TILs were maintained in media consisting of equal volumes of RPMI-1640 and AIM V media (Life Technologies) supplemented with 5% human serum and 3,000 IU of IL2. Coculture assays performed in 96-well U-bottom plates at a 1:1 ratio of T cells to target cells in 200 μL of 1:1 RPMI-1640:AIM V media supplemented with 5% human serum for 16 to 20 hours were screened for IFNγ production in the supernatant via ELISA as previously described (15).

Normal B cells were generated from autologous peripheral blood mononuclear cells (PBMC) as described (16).

**Whole-exome sequencing and RNA-Seq analysis**

Genomic DNA purification, library construction, exome capture of approximately 20,000 coding genes, and next-generation sequencing of 3713 fresh tumor (FrTu) embedded in optimal cutting temperature (OCT; Sakura Finetek) and a matched normal pheresis sample were performed at Personal Genome Diagnostics as previously described (17). In addition, a whole-exome library was prepared using Agilent Technologies SureSelectXT Target Enrichment System for paired-end libraries and subsequently sequenced on a NextSeq 500 desktop sequencer (Illumina). The library was prepped using gDNA (3 μg) isolated from the ten 10-μm OCT sections following the manufacturer’s protocol (Agilent Technologies). Paired-end sequencing was done with an Illumina mid-output flow cell kit (300 cycles). An mRNA sequencing library was prepared from the autologous 3713 tissue culture (TC) line using an Illumina TruSeq RNA library prep kit following the manufacturer’s protocol. RNA-Seq libraries were paired-end sequenced on a HiSeq 2000 sequencer (Illumina) for 100 cycles at the FDA sequencing core laboratory.

Nonsynonymous somatic variants were identified from whole-exome sequencing of 3713 FrTu using filters consisting of a minimum of three variant reads, an 8% variant allele frequency (VAF), less than or equal to a 1% VAF in normal DNA, and absence in the set of SNPs in the 1000 Genomes SNP database or presence in the database at a VAF of less than 1%. Approximately 83% of the single or dinucleotide substitutions represented C-to-T transitions (Supplementary Fig. S1), the common signature for mutations induced by ultraviolet light (18). Further analysis revealed that approximately 1,000 variants were derived from transcripts with expression (expressed as fragments per kilobase per million transcripts or FPKM) between the range of 1 and 900 FPKM units. In an attempt to screen targets expressed to various degrees, but also to limit screening to gene products that were more likely to be recognized by T cells, the top 720 variants, corresponding to a FPKM value of approximately 3 or higher, were chosen for further evaluation (Supplementary Table S1). After annotation, mutated...
transcripts were extracted from the NCBI Reference Sequence, UCSC Known Gene and ENSEMBL databases, and in the case of single-nucleotide variants, peptide sequences encompassing the mutated codon plus the 12 flanking amino acids, except in cases in which derived mutations were present within the first or final 12 amino acids of the protein transcript. For the two frameshift deletions that were identified, the 12 amino acids prior to the deletions were extracted, and sequences beyond the mutation site were translated until the first stop codon was encountered. For the single stop-loss variant that was identified, the 12 amino acids prior to the mutated stop codon were translated, along with downstream coding sequences prior to the first stop codon.

**TMG library construction**

Candidate-mutated peptide sequences were reverse-translate-d and codon optimized using online tools available at Life Technologies and IDT DNA, Inc. Of the 720 variants chosen for evaluation, 718 contained either a single or a dinucleotide nonsynonymous mutation, one contained a frameshift deletion of a single nucleotide and one contained a mutation resulting in the loss of a stop codon. In addition, for 10 of the nonsynonymous mutations, alternatively spliced gene products that gave rise to two peptide sequences differing in regions flanking the mutation site were evaluated. Transcripts were grouped into TMGs encoding between 10 and 12 individual minigenes, with no amino-acid spacers between individual minigenes. A total of 62 TMG constructs were then synthesized (Invitrogen) and cloned into a modified pcDNA3.1 expression vector (Invitrogen). The TMGs were inserted downstream of, and in-frame with, sequences encoding an adenovirus E19 signal-peptide sequence (19) and upstream of, and in-frame with, a LAMP1 endosomal targeting sequence (20), using the In-Fusion Advantage PCR cloning Kit (Clontech) according to the manufacturer’s instructions.

The TMG constructs were linearized by digestion with the NsiI restriction enzyme for 16 hours at 37°C followed by phenol:chloroform:isoamyl alcohol (25:24:1) extraction and ethanol precipitation, and in vitro transcription performed using a T7 IVT kit (Life Technologies) with linear DNA (1 μg) for 2 hours at 37°C followed by 15-minute DNasel treatment, and mRNA was purified using the Qiagen QIAeasy RNA extraction/clean-up Kit (Qiagen) per the manufacturer’s protocol. Autologous B cells transformed with EBV were then electro-transformed as described (9) with 1 to 2 μg of the in vitro–transcribed RNA followed by incubation for 16 to 20 hours at 37°C. Autologous TIL 3713 (100,000 cells) were cocultured with an equal number of transfected EBV cells in 96-well plates overnight at 37°C, with cocultures of 3713 TC cells with autologous TILs serving as a positive control. The IFNγ released in coculture supernatants was measured with an ELISA assay.

**Screening assay and identification of mutated epitopes recognized by TIL 3713**

TMGs that stimulated at least 200 pg/ml of IFNγ and for which the resulting IFNγ concentration was at least twice that of control cocultures (EBV-transformed B cells transfected with the irrelevant green fluorescent protein) were further evaluated. Constructs that encoded the wild-type version of individual minigenes or that had between one and six of the minigenes present in the original TMGs deleted were generated for screening. Mutated candidates that failed to stimulate significant cytokine release from TIL 3713 when deleted or reverted back to wild-type sequences were presumed to encode mutated T-cell epitopes.

To identify the MHC class I restriction elements that presented the mutated epitopes, HEK-293T cells were cotransfected with plasmid DNA corresponding to individual positive TMGs and individual constructs encoding each of the six MHC class I restriction elements expressed by the patient’s normal and tumor cells (HLA-A*02:01; A*29:02, B*44:03, B*51:01, C*15:02, or C*16:01). The Immune Epitope Database (IEDB) NetMHC consensus-binding algorithm (21) was used to identify candidate minimal epitopes and synthesized as crude peptides (Peptide 2.0), pulsed on 3713 EBV B cells, and evaluated for their ability to stimulate significant cytokine release from TIL 3713.

Peptides were picked based on both the IC_{50} and percentile rank with a cutoff of ≤500 nmol/L and 3.0, respectively. Peptides with an RPM (reads per kilobase of transcript per million mapped reads) ranging from 3 to several hundred (determined from RNA-Seq analysis) were coupled to NetMHC IC_{50} and percentile rank to define which peptides to screen. Positive peptides and the corresponding wild-type peptides were synthesized, high-performance liquid chromatography (HPLC)–purified, and ≥95% purity (Peptide 2.0). Autologous EBV-transformed B cells were then pulsed with varying concentrations of the putative minimal epitopes for 2 hours at 37°C, washed once, and evaluated in IFNγ-release assays.

**T-cell receptor analysis**

The frequencies of individual T-cell clonotypes were determined by T-cell receptor (TCR) analysis of bulk PBMC obtained before and after adoptive transfer of bulk infusion TILs, and of CD8+ T cells that were electron-densi ty sorted from a 3713 FrTu digest as described (22). Cell pellets were snap frozen and sent to Adaptive Biotechnologies for genomic DNA extraction and ImmunoSEQ TCRβ survey sequencing. TCR α- and β-chain sequences were identified by amplifying sequences using a 5’RACE protocol as described (23) from T cells that were cloned by limiting dilution from TIL 3713 or from T cells that were sorted based upon upregulation of 4-1BB expression following stimulation with cells pulsed with mutated epitopes (24). Functional TCRs were generated by synthesizing constructs encoding α-chain sequences joined to β-chain sequences with a self-cleaving picornavirus P2A sequence (25) in the pMSGV1 retrawctor vector, and activity was assessed by coculturing TCR-transduced PBMCs with tumor or peptide-pulsed target cells, as described (26). Isolation of CD8+ T cells from PBMCs was carried out using a CD8 T-cell enrichment kit (BD Biosciences).

**Results**

Whole-exome sequencing of fresh uncultured tumor and normal cells from patient 3713 initially indicated that this tumor contained over 4,000 nonsynonymous somatic variants, a relatively high mutational load in comparison with the majority of cutaneous melanomas (27), although melanomas that possess similar or higher mutation rates have been identified in previous studies (28, 29). Expression of the corresponding mutated transcripts was evaluated by RNA-Seq analysis of a T-cell line generated from 3713, FrTu, from which 720 of the most highly expressed mutated gene products were further evaluated.

Sixty-two TMGs, encoding the selected variants plus the 12 upstream and downstream flanking residues were constructed,
and autologous EBV B cells were transfected with in vitro transcribed RNA from these constructs. The autologous TIL 3713 cells used to treat the patient were >98% CD8+ (data not shown) and recognized targets transfected with TMGs 2, 5, 6, 9, 17, 20, 23, 32, 39, and 60 (Fig. 2A).

Initially, we synthesized and tested candidate high-affinity HLA HLA-A*02:01-binding peptides, identified from the mutated transcripts using an algorithm designed to predict binding to MHC class I gene products (21), for recognition by TIL 3713. TIL 3713 cells recognized a mutated SRPX peptide encoded by TMG-2 and a mutated WDR46 peptide encoded by TMG-9 (Table 1; ref. 30).

To identify other mutated antigens recognized by TIL 3713 T cells, individual minigenes were either reverted back to wild-type sequences or deleted from the TMG constructs. Reversion of individual sequences within the TMGs to the appropriate wild-type sequences led to the identification of HELZ2, GCN1L1, AFMID, and PLSCR4 as the antigens targeted in TMG-5, 6, 17, and 60, respectively, whereas evaluation of truncated TMGs led to the identification of TPX2 and SEC22C was recognized in the context of HLA-A*02:01 (Fig. 2B). The results of cocultures with transfected HEK-293T cells confirmed that TIL 3713 recognized SRPX in the context of HLA-A*02:01 (Fig. 2B). Targets transfected with TPX2 and SEC22C were recognized in the context of HLA-B*44:03, whereas targets transfected with PRDX3, HELZ2, GCN1L1, AFMID, PLSCR4, and CENPL were recognized in the context of HLA-

Figure 2.
Screening of patient 3713 autologous infusion bag TILs for reactivity to TMGs. A, autologous B cells transformed with EBV were transfected with IVT RNA from TMG-1 to TMG-62 individually and then cotransfected with autologous infusion bag TIL. IVT RNA expressing GFP was a negative control, and autologous TIL 3713 melanoma cell line (*) was used as a positive control. B, HEK-293T cells were transiently cotransfected with positive patient 3713 TMGs in the presence of patient-specific HLAs (A*020101, A*290201, B*440301, B*510101, C*150101, or C*160101). GFP expression construct was used as a negative control. C, COS7 cells were transiently cotransfected with positive patient 3713 TMGs in the presence of patient-specific HLAs (A*020101, A*290201, B*440301, B*510101, C*150101, or C*160101). GFP expression construct was used as a negative control.
context of HLA-A*29:02 (Fig. 2B). Similar results were observed using COS7 cells transfected with TMGs 2, 5, 6, 17, 20, 23, 32, and 39, but in addition, TIL 3713 recognized COS7 cells transfected with WDR46 in the context of HLA-A*02:01. Responses against COS7 transfectants were generally more robust than responses to HEK-293T transfectants, which may have been responsible for the finding that TIL 3713 recognized COS7 but not HEK-293T cells that were cotransfected with the appropriate class I MHC alleles.

We then evaluated the TCR clonotypes within the autologous 3713 TC line that recognized mutated tumor epitopes. We isolated mutation-reactive TCRs from these clones or from CD137+ T cells that had been FACS sorted from IB TIL 3713 after stimulation with mutated TMGs (Table 2 and Fig. 4). Deep sequencing of TCR Vβ regions revealed that the top 20 clonotypes in the infused TILs ranged in frequencies between 4.5% and 1.3% (Table 2). Analysis of T-cell clones and T cells transduced with TCR α and β pairs isolated from antigen-reactive T cells revealed that 9 of the top 20 clonotypes recognized an individual epitope derived from either the CENPL, SRPX, AFMID, HELZ2, or SEC22 mutated transcripts (Table 2 and Fig. 4A–F). Screening of limiting-dilution clones or T cells that upregulated 4-1BB in response to antigen stimulation did not lead to the isolation of the T cells corresponding to the remaining 11 clonotypes, for which the reactivities remain unknown. The T cells that recognized the mutated CENPL, SRPX, HELZ2, and SEC22 epitopes also recognized autologous 3713 TC cells, whereas AFMID-reactive T cells showed little or no recognition of 3713 TC (Fig. 4). Five of the top 7 clonotypes recognized the mutated SRPX epitope at frequencies ranging between approximately 2% and 4% of the infused TILs, and single clonotypes recognizing the mutated CENPL, HELZ2, SEC22, and AFMID epitopes each represented between 1% and 2% of the infused TILs (Table 2 and Fig. 4C–E). Approximately 12% of the infused TIL 3713 were reactive with an HLA-A*02:01 tetramer prepared with the mutated SRPX peptide (30), which was comparable with the total frequency of the 5 dominant SRPX-reactive clonotypes detected in IB TIL 3713 (14%). The factors responsible for the predominant reactivity of IB TIL 3713 against the mutated SRPX epitope are unknown. One possibility could be the relatively high expression of this gene product (Supplementary Table S1). The 5 dominant SRPX-reactive clonotypes detected in the infused TILs also represented the 5 most dominant T-cell clonotypes in the peripheral blood 5 weeks after adoptive transfer, each of which appeared to be represented in the peripheral blood at levels that were similar or somewhat higher than those observed in the infused TILs (Table 2). Four of the 5 SRPX-reactive clonotypes were also detected approximately 1 year after transfer at levels that ranged between 1% and 1.9% of peripheral T cells, and clonotypes reactive with the CENPL, HELZ2, and SEC22C epitopes represented 1.2, 1.0, and 0.5%, respectively, of peripheral T cells at this time (Table 2). T-cell clonotypes reactive with the mutated CENPL, SRPX, HELZ2, SEC22, and AFMID epitopes were represented in the 100 most

Table 1. Mutated antigens recognized by TIL 3713

<table>
<thead>
<tr>
<th>Gene</th>
<th>Transcript ID</th>
<th>Chromosome: position</th>
<th>Amino-acid change</th>
<th>cDNA change</th>
<th>Mutated amino-acid sequence</th>
<th>Wild-type amino-acid sequence</th>
<th>HLA restriction element</th>
<th>Mutant IC₅₀ (nmol/L)</th>
<th>Mutant rank</th>
<th>Wild-type IC₅₀ (nmol/L)</th>
<th>Wild-type rank</th>
</tr>
</thead>
<tbody>
<tr>
<td>SRPX</td>
<td>uc0044dyv.2</td>
<td>chr3:38303559</td>
<td>P55L</td>
<td>C164T</td>
<td>T/LWSPIKVK</td>
<td>T/LWSPIKVK</td>
<td>A’02:01</td>
<td>12</td>
<td>0.6</td>
<td>12,683</td>
<td>18</td>
</tr>
<tr>
<td>WDR46</td>
<td>uc0033ods.3</td>
<td>chr3:3254984</td>
<td>T300I</td>
<td>C899T</td>
<td>F/TLYLVSV</td>
<td>F/TLYLVSV</td>
<td>A’02:01</td>
<td>5</td>
<td>0.3</td>
<td>8</td>
<td>0.4</td>
</tr>
<tr>
<td>PRDX3</td>
<td>uc0011ec.3</td>
<td>chr10:2093592</td>
<td>P50L</td>
<td>C302T</td>
<td>F/VLDFTFR</td>
<td>F/VLDFTFR</td>
<td>A’02:01</td>
<td>16</td>
<td>0.4</td>
<td>7</td>
<td>0.3</td>
</tr>
<tr>
<td>HELZ2</td>
<td>uc002yztm.2</td>
<td>chr20:6298871</td>
<td>D614N</td>
<td>G1840T</td>
<td>Q/TPVLYGO</td>
<td>Q/TPVLYGO</td>
<td>A’02:01</td>
<td>18</td>
<td>0.4</td>
<td>144</td>
<td>1.2</td>
</tr>
<tr>
<td>GCN1L</td>
<td>uc001ttx.3</td>
<td>chr12:120599720</td>
<td>P769L</td>
<td>C2306T</td>
<td>IMQLAGELY</td>
<td>IMQLAGELY</td>
<td>A’02:01</td>
<td>43</td>
<td>0.4</td>
<td>49</td>
<td>0.4</td>
</tr>
<tr>
<td>AFMID</td>
<td>uc002juz.3</td>
<td>chr17:6198784</td>
<td>A52V</td>
<td>C155T</td>
<td>EVPLLFFF</td>
<td>EVPLLFFF</td>
<td>A’29:02</td>
<td>156</td>
<td>1.2</td>
<td>1,003</td>
<td>2.8</td>
</tr>
<tr>
<td>PLSCR4</td>
<td>uc010hu.3</td>
<td>chr1:45914466</td>
<td>R247C</td>
<td>C739T</td>
<td>R/TGCPSTY</td>
<td>R/TGCPSTY</td>
<td>A’29:02</td>
<td>247</td>
<td>1.6</td>
<td>586</td>
<td>2.2</td>
</tr>
<tr>
<td>CENPL</td>
<td>uc002oov.4</td>
<td>chr1:17776589</td>
<td>P79L</td>
<td>C2367T</td>
<td>T/LTSLTL</td>
<td>T/LTSLTL</td>
<td>A’29:02</td>
<td>21</td>
<td>0.3</td>
<td>13</td>
<td>0.2</td>
</tr>
<tr>
<td>TPK2</td>
<td>uc010gvd.1</td>
<td>chr20:30371636</td>
<td>H458Y</td>
<td>C1480T</td>
<td>T/EDEHFEHY</td>
<td>T/EDEHFEHY</td>
<td>B’44:03</td>
<td>153</td>
<td>0.5</td>
<td>9,325</td>
<td>4.4</td>
</tr>
<tr>
<td>SEC22</td>
<td>uc003cd.3</td>
<td>chr3:42597481</td>
<td>H218Y</td>
<td>C652T</td>
<td>A/ESHLQVAV</td>
<td>A/ESHLQVAV</td>
<td>B’44:03</td>
<td>13</td>
<td>0.2</td>
<td>589</td>
<td>11</td>
</tr>
</tbody>
</table>
T-cell clones or appropriate TCR clonotypes were evaluated due to our inability to identify of melanoma FrTu samples (21). None of the remaining study evaluating the reactivity of T cells isolated from a panel that T cells recognizing tumor-specific antigens with limited or no expression in normal tissues. Many long-term complete responses to TILs in melanoma patients receiving oligoclonal populations of autologous TILs (3) were not associated with normal tissue toxicity, presumably resulting from the expression of these antigens in normal melanocytes. Durable complete tumor regressions were observed in 3 of 20 melanoma and 1 of 18 synovial cell sarcoma patients who received autologous T cells directed to the cancer-germline antigen NY-ESO-1 (33). However, most common cancers express little of this antigen, which limits its usefulness therapeutically. Although 1 of 9 patients who received T cells directed to a MAGE-A3 epitope had a long-term complete response, 3 patients experienced unexpected severe neurologic toxicity (34).

The durable complete regressions observed in about 20% of melanoma patients receiving oligoclonal populations of autologous TILs (3) were not associated with normal tissue toxicity, indicating that clinical responses can be mediated by T cells recognizing antigens with limited or no expression in normal tissues. Many long-term complete responses to TILs in melanoma...
Table 2. Sequence and reactivity of dominant T-cell clonotypes in TIL 3713

<table>
<thead>
<tr>
<th>Infused TILs</th>
<th>TR-BV CDR3b aa sequence</th>
<th>Autologous tumor reactivity</th>
<th>Clone/TRB pair</th>
<th>Antigen reactivity</th>
<th>Pre-PBMC Rank</th>
<th>Frequency (%)</th>
<th>TR-BV T cells (FrTu) Rank</th>
<th>Frequency (%)</th>
<th>Post 1 month Rank</th>
<th>Frequency (%)</th>
<th>Post 1 year Rank</th>
<th>Frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>4.5</td>
<td>ATGTGGNDYEQYF Yes</td>
<td>TCR T4</td>
<td>CENPL</td>
<td>52,466</td>
<td>0.0005</td>
<td>19/481 1.0/0.05</td>
<td>7</td>
<td>2.8</td>
<td>8</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>3.9</td>
<td>ASLGKDFKAF Yes</td>
<td>TCR MP1</td>
<td>SRPX</td>
<td>ND</td>
<td>&lt;0.0001</td>
<td>86/ND 0.24/0.001</td>
<td>1</td>
<td>4.5</td>
<td>4</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>3.5</td>
<td>ASSQDEPHYEYQVF NT</td>
<td>Not identified</td>
<td>HLA-DR</td>
<td>ND</td>
<td>&lt;0.0001</td>
<td>19/481 1.0/0.05</td>
<td>7</td>
<td>2.8</td>
<td>8</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>2.8</td>
<td>ASSXIQYVYQVF Yes</td>
<td>Clone XY-51</td>
<td>SRPX</td>
<td>49,395</td>
<td>0.0005</td>
<td>22/591 0.91/0.04</td>
<td>2</td>
<td>4.5</td>
<td>ND</td>
<td>&lt;0.0003</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>2.6</td>
<td>ASSGQGPEYYQVF Yes</td>
<td>Clone XY-6</td>
<td>SRPX</td>
<td>ND</td>
<td>&lt;0.0001</td>
<td>10/198 1.6/0.01</td>
<td>3</td>
<td>4.3</td>
<td>6</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>2.6</td>
<td>ASSGAAIDTDFYQVF Yes</td>
<td>Clone XY-3</td>
<td>SRPX</td>
<td>27,655</td>
<td>0.0012</td>
<td>3/963 3.2/0.02</td>
<td>4</td>
<td>4.1</td>
<td>7</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>2.5</td>
<td>ASSEGFQGNTYQVF Yes</td>
<td>Clone XY-3</td>
<td>SRPX</td>
<td>ND</td>
<td>&lt;0.0001</td>
<td>3/963 3.2/0.02</td>
<td>4</td>
<td>4.1</td>
<td>7</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>2.1</td>
<td>ASSQDGGAKQNYQVF No</td>
<td>TCR 8</td>
<td></td>
<td>45,870</td>
<td>0.0006</td>
<td>507/949 0.02/0.008</td>
<td>6</td>
<td>3.4</td>
<td>17</td>
<td>0.9</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>2.0</td>
<td>ASSQGQPQPQHF No</td>
<td>TCR 9</td>
<td></td>
<td>ND</td>
<td>&lt;0.0001</td>
<td>39/60 0.54/0.22</td>
<td>10</td>
<td>1.8</td>
<td>11</td>
<td>0.8</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>1.8</td>
<td>ASSLSNHTQYF Yes</td>
<td>TCR T8-1 HELZ2</td>
<td></td>
<td>15,120</td>
<td>0.0017</td>
<td>2/112 6.5/0.15</td>
<td>9</td>
<td>2.2</td>
<td>12</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>1.7</td>
<td>ASGPPGGLTYEQVF NT</td>
<td>Not identified</td>
<td></td>
<td>ND</td>
<td>&lt;0.0001</td>
<td>80/1291 0.26/0.02</td>
<td>15</td>
<td>1.4</td>
<td>140</td>
<td>0.09</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>1.7</td>
<td>ASSLHSQSSYEQVF NT</td>
<td>Not identified</td>
<td></td>
<td>ND</td>
<td>&lt;0.0001</td>
<td>80/1291 0.26/0.02</td>
<td>15</td>
<td>1.4</td>
<td>140</td>
<td>0.09</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>1.6</td>
<td>SVEDRPGFQYGF Yes</td>
<td>Clone XY52</td>
<td>SEC2C</td>
<td>ND</td>
<td>&lt;0.0001</td>
<td>41,910 0.55/0.024</td>
<td>17</td>
<td>1.3</td>
<td>28</td>
<td>0.5</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>1.6</td>
<td>ASSLAQMQPQHF NT</td>
<td>Not identified</td>
<td></td>
<td>44,967</td>
<td>0.0007</td>
<td>35/40 0.56/0.33</td>
<td>8</td>
<td>2.7</td>
<td>9</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>1.6</td>
<td>ASSQYAVRGDEAFF NT</td>
<td>Not identified</td>
<td></td>
<td>ND</td>
<td>&lt;0.0001</td>
<td>8/507 2.0/0.046</td>
<td>59</td>
<td>0.3</td>
<td>44</td>
<td>0.3</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>1.5</td>
<td>ASSSLGAGEAFF NT</td>
<td>Not identified</td>
<td></td>
<td>ND</td>
<td>&lt;0.0001</td>
<td>8/507 2.0/0.046</td>
<td>59</td>
<td>0.3</td>
<td>44</td>
<td>0.3</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>1.5</td>
<td>ASLLEIYAFF NT</td>
<td>Not identified</td>
<td></td>
<td>5.839</td>
<td>0.0027</td>
<td>1/268 9.7/0.079</td>
<td>22</td>
<td>0.9</td>
<td>62</td>
<td>0.3</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>1.4</td>
<td>ASSHQAGALNYQVF Yes</td>
<td>TCR M1-2</td>
<td>ARMID</td>
<td>ND</td>
<td>&lt;0.0001</td>
<td>94/262 0.20/0.079</td>
<td>41</td>
<td>0.5</td>
<td>56</td>
<td>0.3</td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>1.3</td>
<td>ASSPQGEGF NT</td>
<td>Not identified</td>
<td></td>
<td>ND</td>
<td>&lt;0.0001</td>
<td>52/909 0.02/0.001</td>
<td>50</td>
<td>0.4</td>
<td>48</td>
<td>0.3</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>1.3</td>
<td>ASLERVGSTDFYQVF No</td>
<td>Not identified</td>
<td></td>
<td>ND</td>
<td>&lt;0.0001</td>
<td>52/909 0.02/0.001</td>
<td>50</td>
<td>0.4</td>
<td>48</td>
<td>0.3</td>
<td></td>
</tr>
</tbody>
</table>

*The rearranged TR-BV region sequences of the indicated T-cell populations were analyzed by deep-sequencing; nucleotide sequences present at two or more copies were ranked from the highest to the lowest frequency, and amino-acid sequences of the CDR3 regions were determined, as described in Materials and Methods.

*ND, not detected within the limits of the assay (0.0001% for pre-PBMC, 0.001% for PD-1+ and PD-1− CD8+ T cells (FrTu), 0.0004% for post 1 month, and 0.0003% for post 1 year samples).

*NT, not tested.
did not involve recognition of shared nonmutated antigens but, rather, contained dominant populations of T cells recognizing patient-specific neoantigens (7, 9, 35, 36). The melanomas evaluated in these studies contained between approximately 250 and 3,000 somatic nonsynonymous mutations (7, 9, 35, 36; S.A. Rosenberg, unpublished data), suggesting no direct association between the response to adoptive immunotherapy and mutation rate, a conclusion further supported by ongoing durable objective response that was observed in a patient with cholangiocarcinoma following the adoptive transfer of a highly enriched population of autologous CD8 T cells reactive with a mutated ERBB2IP protein expressed by autologous cholangiocarcinoma tumor cells possessing only 26 nonsynonymous somatic mutations (10) and in a melanoma patient with only 70 nonsynonymous somatic mutations (9). The effects of mutations that give rise to neoepitopes, combined with intrinsic features of tumor antigen–reactive T cells—avidity, differentiation state, and proliferative potential (22, 37)—all influence responses to immunotherapy. These factors are likely, for the most part, to be independent of the number of neoepitope targets expressed by patients’ tumors.

T cells recognizing neoantigens probably play a role in clinical responses to immune checkpoint inhibitors. In one report, clinical responses in patients with metastatic melanoma to ipilimumab or tremelimumab, antibodies directed against the inhibitory protein CTLA-4, were associated with the number of nonsynonymous somatic mutations detected in those cancers (11). Translation of the sequences surrounding the nonsynonymous mutations led to the identification of a 4-aminooacid motif, termed a neoantigen signature, which was associated with clinical response to anti–CTLA-4 therapy, although this finding has not been confirmed in additional studies. In a second study, clinical responses of patients with non–small cell lung cancer to administration of pembrolizumab, an antibody directed toward the immune checkpoint inhibitor PD-1, were associated with mutational burden, and treatment was associated with the peripheral expansion of T cells reactive with a neoantigen target in one of the patients (12).

**Figure 4.** Reactivity of clones or TCRs corresponding to predominant clonotypes in TIL 3713. Responses of allogeneic whole PBMCs (A–C) or CD8–enriched T cells (D) transduced with TCRs reactive with the mutated SRPX (A), AFMID (B), HELZ2 (C), or CENPL epitopes were evaluated by measuring the release of IFNγ in response to T2 cells (A) or autologous EBV B cells (B–D) pulsed with the appropriate peptides. Transduced T cells were also evaluated for their ability to release IFNγ in response to either the autologous TC line or an allogeneic melanoma TC line. In addition, T-cell clones isolated from TILs that were reactive with the mutated SRPX (E) or the mutated SEC22C epitope (F) were evaluated for their ability to upregulate 4-1BB in response to autologous normal B cells (E) or EBV B cell (F) targets pulsed with the appropriate peptides or the autologous TC line (graphs represent two independent experimental repeats).
Here, we identified 10 distinct mutated T-cell epitopes as targets of the autologous TILs out of the 720 nonsynonymous somatic mutations with the highest transcript expression in the 3713 tumor. Between 1 and 5 of the 20 most frequent T-cell clonotypes present within the infused T-cell population, which ranged in frequency between 4.5% and 1.4% of total T cells, recognized the mutated CENPL, SRPX, HELZ2, AFMID, and/or SEC22C antigens and autologous tumor cells. All of the reactive clonotypes were detected at lower but significant levels approximately 1 year after transfer, suggesting an important role of mutation-reactive T cells in the ongoing complete tumor regression observed in some patients receiving adoptive treatment with autologous TILs (7–9).

Overall, these observations suggest that additional clinical studies focused on targeted neoantigens are warranted. Additional treatment strategies that take advantage of whole-exome and RNA-Seq data include the isolation and expansion of T cells specific for patient neoantigens using MHC multimers generated by peptide exchange (38), the transduction of patient PBMCs with TCRs isolated from neoantigen-reactive T cells, and the development of cancer vaccines targeting potent neoantigens. This information can also serve as the basis of therapies combining the checkpoint inhibitors, the adoptive transfer of neoantigen-reactive T cells, and neoantigen vaccines that may result in enhanced therapeutic effects.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

References


Cancer Immunology Research

Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens

Todd D. Prickett, Jessica S. Crystal, Cyrille J. Cohen, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/2326-6066.CIR-15-0215

Supplementary Material
Access the most recent supplemental material at:
http://cancerimmunolres.aacrjournals.org/content/suppl/2016/06/16/2326-6066.CIR-15-0215.DC1

Cited articles
This article cites 38 articles, 18 of which you can access for free at:
http://cancerimmunolres.aacrjournals.org/content/4/8/669.full#ref-list-1

Citing articles
This article has been cited by 13 HighWire-hosted articles. Access the articles at:
http://cancerimmunolres.aacrjournals.org/content/4/8/669.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link:
http://cancerimmunolres.aacrjournals.org/content/4/8/669
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.